How many days after the last Omnadren 250 injection should I wait before starting PCT?

Wait approximately 14–18 days after your final injection before beginning SERM-based PCT. This window is derived from the decanoate ester's half-life of roughly 14–16 days; starting SERMs earlier places them in competition with still-circulating exogenous testosterone, reducing their ability to stimulate LH and FSH secretion from the pituitary.

Which PCT medications work best after a multi-ester testosterone blend like Omnadren 250?

Tamoxifen (Nolvadex) and clomiphene citrate (Clomid) are the two evidence-supported SERMs for HPG axis recovery after suppressive testosterone cycles. Tamoxifen at 40 mg/day for two weeks then 20 mg/day for two weeks is widely used; clomiphene at 50 mg/day for four weeks is an alternative, particularly for athletes with blunted tamoxifen response.

How long does full testosterone recovery take after an Omnadren 250 cycle?

Full endogenous testosterone restoration typically takes six to twelve weeks from PCT initiation. Recovery speed depends on cycle duration, total weekly dose, and individual HPG axis responsiveness. Serial blood panels — measuring LH, FSH, and total testosterone at weeks two, four, and eight of PCT — are the most reliable way to confirm recovery objectively rather than relying on subjective well-being alone.

Why does Omnadren 250 come in single-use 1 ml ampoules rather than a multi-dose vial?

Single-use ampoules eliminate the need for repeated needle puncture of a shared rubber stopper, removing a primary contamination pathway during cycle administration. Each ampoule is opened, drawn, and discarded in one session. This sterility advantage is especially relevant during long cycles where even minor injection-site infections could require antibiotic treatment that complicates PCT timing.

Is 250 mg/ml a suitable concentration for measuring precise doses during the end-of-cycle taper phase?

Yes — 250 mg/ml is among the lowest-concentration presentations available for a four-ester testosterone blend, which simplifies dose arithmetic during taper phases. At this concentration, a standard 1 ml ampoule delivers exactly 250 mg, and half an ampoule delivers 125 mg, making incremental dose reductions straightforward without requiring estimation or dilution calculations before PCT begins. (2) angle_used

Trusted Brand

PharmaSwiss

Omnadren 250 250mg/ml 5x1ml Ampullen by PharmaSwiss

Name: Omnadren 250 250mg/ml 5x1ml Ampoules by PharmaSwiss
Brand: PharmaSwiss
SKU: INJ-TMIX-PHS-250-028
Price: 20.00 EUR
Availability: InStock

Omnadren 250 by PharmaSwiss is a four-ester injectable testosterone blend dosed at 250 mg/ml per single-use ampoule, specifically reviewed here through the lens of Post-Cycle Therapy planning — covering the timing, hormonal recovery sequence, and washout dynamics that govern a safe transition off cycle. Each ampoule contains propionate, phenylpropionate, isocaproate, and decanoate esters whose combined half-life profile directly determines when SERM-based PCT should commence. Batch-release quality is ensured through HPLC ester-fraction verification and LAL endotoxin screening; every ampoule leaves the PharmaSwiss facility only after both analytical checkpoints are cleared.

€20.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Graduated four-ester elimination profile gives precise pharmacokinetic data for calculating PCT start dates
Single-use 1 ml ampoule format preserves sterility across every injection throughout the suppressive cycle phase
250 mg/ml concentration enables straightforward taper arithmetic — no dilution or estimation required
HPLC-confirmed ester proportions ensure each batch delivers a reproducible half-life curve for reliable washout prediction
LAL endotoxin testing on every production lot minimises the risk of injection-related complications that could delay PCT
PharmaSwiss GMP-compliant manufacturing provides batch traceability important for clinical monitoring during cycle and recovery
Five individual ampoules per pack allow cycle-end dose reduction by reducing weekly injection volume without splitting multi-dose vials

Phase	Dosage	Note
Cycle (weeks 1–10)	250–500 mg/week (1–2 ampoules)	Establish suppression duration; cycle length directly determines the depth of HPG axis suppression and therefore PCT length
Taper (weeks 9–10)	250 mg/week (1 ampoule)	Reducing weekly dose allows partial endogenous LH rebound before full cessation; 250 mg/ml concentration simplifies half-dose measurement
Washout (days 1–18 post-last injection)	0 mg	Decanoate ester requires 14–18 days post-injection before serum testosterone drops to a level where SERMs can generate meaningful LH/FSH stimulation
PCT Week 1–2	Tamoxifen 40 mg/day or Clomiphene 50 mg/day	Initiate SERM after washout window; tamoxifen acts at pituitary estrogen receptor to disinhibit LH and FSH pulsatility
PCT Week 3–4	Tamoxifen 20 mg/day or Clomiphene 25–50 mg/day	Taper SERM dose as endogenous LH and FSH levels recover; confirm via blood panel at week 2 of PCT
Post-PCT monitoring (weeks 5–12)	No exogenous androgens; blood panels only	LH, FSH, and total testosterone panels at weeks 4, 8, and 12 post-PCT confirm full HPG axis restoration

Key takeaways

Calculate your PCT start date from the decanoate ester's 14–16 day half-life.
Begin SERM therapy only after the 14–18 day washout window has elapsed.
Monitor LH, FSH, and testosterone levels at weeks two, four, and eight of PCT.
Use single-dose ampoules to eliminate injection-site contamination throughout the cycle.
Choose the 250 mg/ml concentration for accurate taper-phase dose increments.

What Omnadren 250 Is and Why Its Ester Profile Defines Your PCT Window

Omnadren 250 is a pharmaceutical-grade, oil-based testosterone blend containing four esterified testosterone fractions — propionate (30 mg), phenylpropionate (60 mg), isocaproate (60 mg), and decanoate (100 mg) — manufactured by PharmaSwiss at 250 mg/ml in single-use 1 ml ampoules. The composition of this blend governs its elimination kinetics, and those kinetics are the single most important variable an athlete must understand before scheduling Post-Cycle Therapy. PharmaSwiss produces Omnadren 250 under GMP-compliant conditions, with HPLC confirming each ester fraction and LAL testing verifying endotoxin limits in every released batch.

How the Four-Ester Elimination Curve Determines PCT Start Date

The decanoate fraction carries an approximate half-life of 14–16 days, meaning that meaningful serum testosterone suppression from exogenous androgens persists well beyond the last injection. Post-Cycle Therapy initiation timed too early — before serum exogenous testosterone has dropped sufficiently — will place SERM molecules (tamoxifen or clomiphene) in direct competition with still-elevated androgenic ligands, substantially blunting pituitary LH and FSH recovery. The clinically recommended approach, derived from ester half-life arithmetic, places PCT start at approximately 14–18 days after the final Omnadren 250 injection. Compared to single short-ester testosterone products where PCT begins within 3–5 days post-injection, the long-tail decanoate fraction in Omnadren 250 demands a markedly extended washout window before SERM administration becomes pharmacologically meaningful.

Recommended PCT Sequence Following an Omnadren 250 Cycle

Once the washout window has elapsed, the hypothalamic-pituitary-gonadal (HPG) axis begins receiving endogenous GnRH pulses again, but LH and FSH secretion remain suppressed without pharmacological support. Tamoxifen at 40 mg/day for weeks one and two, tapering to 20 mg/day for weeks three and four, represents the standard SERM protocol cited across sports medicine literature for restoring gonadotropin pulsatility. Serum LH, FSH, and total testosterone measurements at weeks two and four of PCT quantify HPG axis recovery objectively. Clomiphene citrate (50 mg/day for four weeks) provides an alternative for athletes who respond poorly to tamoxifen, as clomiphene acts at both hypothalamic and pituitary estrogen receptors.

Monitoring and Recovery Timeline

Full testicular steroidogenic recovery after a suppressive testosterone cycle typically spans six to twelve weeks from PCT initiation, depending on cycle length, total androgen dose, and individual HPG axis resilience. Blood panels measuring LH, FSH, total testosterone, and SHBG at weeks two, four, and eight of PCT provide actionable data to adjust SERM dose or duration. PharmaSwiss's single-dose ampoule format reduces contamination risk during cycle administration, which indirectly protects the athlete from cycle-extending complications that could prolong suppression and delay PCTstart.

Usage

Calculate your washout window before your last injection: Given Omnadren 250's decanoate fraction, mark day 14–18 post-final-injection as your PCT start date on your calendar before you administer the last ampoule.
Inspect the ampoule: Hold the 1 ml glass ampoule to the light to verify clarity and absence of particles; PharmaSwiss ampoules are single-use — discard any with visible contamination or compromised seals.
Prepare injection site aseptically: Swab the gluteal or lateral deltoid injection site with an alcohol wipe; allow full drying before insertion to avoid introducing alcohol into the oil-based solution.
Administer the full ampoule content in one session: Single-dose ampoules are designed for complete single-use draw — draw the full 1 ml into your syringe immediately after snapping the ampoule head.
Log injection date and dose: Record each injection date so you can calculate the exact washout window; accurate record-keeping is essential for timing SERM introduction correctly during PCT.
Initiate PCT at the correct interval: After the 14–18 day washout, begin SERM therapy as planned; obtain baseline LH, FSH, and total testosterone bloodwork on PCT day one so you have a quantifiable starting point for recovery tracking.

Warnings

Contraindications: Omnadren 250 is contraindicated in individuals with androgen-sensitive prostate or breast carcinoma, severe hepatic impairment, hypercalcaemia, untreated polycythaemia, or known hypersensitivity to any ester fraction or excipient. Individuals with pre-existing cardiovascular disease should not commence a suppressive testosterone cycle without cardiology clearance, as endogenous testosterone suppression during and after the cycle alters lipid profiles and haematocrit.

Side Effects: Exogenous testosterone administration suppresses endogenous LH and FSH via negative HPG axis feedback, leading to testicular atrophy and impaired spermatogenesis that persists until PCT restores gonadotropin pulsatility. Aromatase-mediated conversion to oestradiol can cause gynaecomastia and water retention; aromatase inhibitor use during cycle and appropriate SERM selection during PCT mitigate these effects. Erythrocytosis (elevated haematocrit) is a dose-dependent risk requiring monitoring.

Monitoring: Serum LH, FSH, total testosterone, haematocrit, and lipid panel should be measured at cycle baseline, mid-cycle, and at weeks 2, 4, and 8 of PCT. An elevated haematocrit above 52% warrants cycle interruption. Sperm count assessment is advisable for athletes with fertility concerns, as spermatogenesis recovery may lag behind hormonal normalisation by several months.

PCT: Do not initiate SERM-based PCT until 14–18 days post-final Omnadren 250 injection to allow decanoate ester clearance. Tamoxifen (40 mg/day for two weeks, then 20 mg/day for two weeks) or clomiphene citrate (50 mg/day for four weeks) are the standard pharmacological interventions; concurrent use of both is sometimes practised but increases the risk of mood-related side effects and requires medical supervision.

Frequently asked questions

How many days after the last Omnadren 250 injection should I wait before starting PCT?: Wait approximately 14–18 days after your final injection before beginning SERM-based PCT. This window is derived from the decanoate ester's half-life of roughly 14–16 days; starting SERMs earlier places them in competition with still-circulating exogenous testosterone, reducing their ability to stimulate LH and FSH secretion from the pituitary.
Which PCT medications work best after a multi-ester testosterone blend like Omnadren 250?: Tamoxifen (Nolvadex) and clomiphene citrate (Clomid) are the two evidence-supported SERMs for HPG axis recovery after suppressive testosterone cycles. Tamoxifen at 40 mg/day for two weeks then 20 mg/day for two weeks is widely used; clomiphene at 50 mg/day for four weeks is an alternative, particularly for athletes with blunted tamoxifen response.
How long does full testosterone recovery take after an Omnadren 250 cycle?: Full endogenous testosterone restoration typically takes six to twelve weeks from PCT initiation. Recovery speed depends on cycle duration, total weekly dose, and individual HPG axis responsiveness. Serial blood panels — measuring LH, FSH, and total testosterone at weeks two, four, and eight of PCT — are the most reliable way to confirm recovery objectively rather than relying on subjective well-being alone.
Why does Omnadren 250 come in single-use 1 ml ampoules rather than a multi-dose vial?: Single-use ampoules eliminate the need for repeated needle puncture of a shared rubber stopper, removing a primary contamination pathway during cycle administration. Each ampoule is opened, drawn, and discarded in one session. This sterility advantage is especially relevant during long cycles where even minor injection-site infections could require antibiotic treatment that complicates PCT timing.
Is 250 mg/ml a suitable concentration for measuring precise doses during the end-of-cycle taper phase?: Yes — 250 mg/ml is among the lowest-concentration presentations available for a four-ester testosterone blend, which simplifies dose arithmetic during taper phases. At this concentration, a standard 1 ml ampoule delivers exactly 250 mg, and half an ampoule delivers 125 mg, making incremental dose reductions straightforward without requiring estimation or dilution calculations before PCT begins. (2) angle_used

Manufacturer

PharmaSwiss is a Central and Eastern European pharmaceutical company with manufacturing and distribution operations historically rooted in Slovakia, where it was established as a regional specialty pharma producer serving both prescription and OTC markets. The company built its reputation by positioning branded generics and licensed pharmaceutical products to professional standards aligned with European regulatory expectations — a foundation that carried over into its injectable testosterone line. PharmaSwiss's Omnadren 250 represents the brand's longest-standing injectable androgen product, predating many of the Eastern European generic competitors that entered the market subsequently. The company's approach to quality is documented through GMP-aligned production practices, HPLC analytical verification of active ester content, and LAL endotoxin testing before batch release — a quality architecture consistent with EU-market parenteral product standards.

Product details

Brand	PharmaSwiss
Active ingredient	testosterone mix
Also known as	Sustanon, Omnadren, Testosterone-Mischung, Sustanon 250, Omnadren 250, PharmaSwiss Sustanon
Strength	250 mg
Form	Ampullen
Pack size	5 pieces
Item number	INJ-TMIX-PHS-250-028

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Sustandrol 250mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

GMP Standard

Sustandrol 250mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Sustandrol is a GMP-certified injectable testosterone blend formulated at 250 mg/ml in single-dose 1 ml glass ampoules, manufactured by Balkan Pharmaceuticals at their Chișinău facility under validated pharmaceutical production standards. The four-ester testosterone matrix — propionate, phenylpropionate, isocaproate, and decanoate — delivers a multi-phase serum release profile suited to weekly or bi-weekly injection protocols. Every released batch carries verified analytical documentation: container-closure integrity is confirmed through glass-fusion sealing, potency through HPLC quantification, and endotoxin safety through LAL testing before any unit leaves the production site.

€42.00

High Concentration

Suste-Testosterone 250mg 250mg/ml 10ml Vial by Beligas Pharmaceuticals

Suste-Testosterone 250mg by Beligas Pharmaceuticals is a four-ester testosterone blend formulated at 250mg/ml in a 10ml multi-dose vial, purpose-engineered as the continuous androgenic platform around which advanced multi-compound stacks are architecturally constructed. The staggered ester cascade — spanning rapid-onset propionate through extended-release decanoate — sustains uninterrupted androgenic serum coverage that preserves receptor-priming conditions for every co-administered anabolic throughout the full cycle length. Manufacturing quality is anchored by GMP-certified aseptic filling, per-batch HPLC potency verification, and LAL endotoxin clearance; each released lot carries traceable analytical documentation directly linking the vial to its production record.

€39.00

Verified Manufacturer

Suste-Testosterone 400mg 400mg/ml 10ml Vial by Beligas Pharmaceuticals

Suste-Testosterone 400mg is a high-concentration, oil-based injectable testosterone blend containing four distinct ester fractions — propionate, phenylpropionate, isocaproate, and decanoate — combined at 400mg/ml in a 10ml multi-dose vial, engineered to deliver a continuous androgenic release profile across a wide pharmacokinetic window. Each ester contributes a non-overlapping release phase: the shortest ester activates within 24 hours, while the decanoate component sustains serum testosterone for up to 18–21 days per injection cycle. Quality is locked in at two production stages — raw-material identity confirmed by HPLC against certified reference standards, and finished vials cleared by LAL endotoxin assay before lot release.

€48.00

Susten-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Top Seller

Susten-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Susten-250 is a four-ester testosterone blend formulated at 250 mg/ml by BM Pharmaceuticals, purpose-suited as the anabolic backbone of structured steroid stacks. Its staggered ester release — from propionate's rapid onset through decanoate's sustained tail — gives stack designers the hormonal continuity needed to support both bulking compounds and lean-mass agents across a full cycle. Every production batch is released only after passing HPLC potency verification and LAL endotoxin screening; sterility is confirmed per pharmacopoeial requirements before any ampoule leaves the facility.

€42.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00